Peptomyc Company
Peptomyc focuses on the development of a new generation of cell-penetrating peptides targeting the Myconcoprotein for cancer treatment.
Investors
Founded Date:
2014-12-01
Total Funding:
22792000.0
Investor Type:
For Profit
Employee Number:
1-10
Funding Status:
Early Stage Venture
Technology:
Data-driven Technologies
Last Funding Type:
Venture - Series Unknown
Investors Number:
10.0
Last Funding Date:
2022-01-18
Industry:
Clinical Development
Headquarters:
Barcelona, Catalonia, Spain
Estimated Revenue:
Less than $1M